Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.
The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.
The regulator said Viatris breached restrictions imposed on it during an investigation by "implementing changes to key members of its UK management team" without consent and failing to notify authorities of the breach.
Viatris did not immediately reply to MT Newswires' request for comment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。